Last $2.22 USD
Change Today -0.05 / -2.20%
Volume 138.8K
CBMX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

combimatrix corp (CBMX) Snapshot

Open
$2.27
Previous Close
$2.27
Day High
$2.30
Day Low
$2.22
52 Week High
08/6/13 - $4.55
52 Week Low
05/12/14 - $2.01
Market Cap
24.6M
Average Volume 10 Days
399.2K
EPS TTM
$-2.30
Shares Outstanding
11.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COMBIMATRIX CORP (CBMX)

Related News

No related news articles were found.

combimatrix corp (CBMX) Related Businessweek News

No Related Businessweek News Found

combimatrix corp (CBMX) Details

CombiMatrix Corporation provides molecular diagnostic solutions and clinical support services. It focuses on miscarriage analysis, prenatal testing, and pediatric genetics, as well as offers DNA-based testing for the detection of genetic abnormalities. The company develops and markets molecular testing services for prenatal/postnatal developmental disorders and hematology/oncology genomics. Its developmental disorder suite of array tests focus on the prenatal and postnatal application of microarrays in diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features, and autism spectrum disorders. The company’s oncology diagnostic tests include a series of diagnostic microarray tests that provide additional genomic information to physicians through the genetic analysis of blood, tissue, or biopsy samples. The microarray testing addresses various common hematological malignancies primarily chronic lymphocytic leukemia. The company serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California.

43 Employees
Last Reported Date: 03/24/14
Founded in 1995

combimatrix corp (CBMX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $287.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $262.0K
Compensation as of Fiscal Year 2013.

combimatrix corp (CBMX) Key Developments

CombiMatrix Corporation Announces Contractual Agreement with Stratose

CombiMatrix Corporation announced that it has entered into a contractual agreement with Stratose for coverage of CombiMatrix's diagnostic laboratory services.

CombiMatrix Corporation's Pediatric Development Disorders Analysis Test Granted Conditional Approval from New York State Department of Health

CombiMatrix Corporation announced that its chromosomal microarray analysis (CMA) test to identify development disorders in pediatric patients, the CombiSNP(TM) Array for Pediatric Analysis, has received conditional approval from the New York Department of Health for testing on patient samples. In 2013, the New York Department of Health granted CombiMatrix approval to market its CombiSNP(TM) CMA test for miscarriage analysis. CMA testing for pediatric development disorders, such as the company's CombiSNP(TM) CMA test, is recommended by the American College of Medical Genetics for individuals with developmental delays, birth defects, physical deformities or autism or autism spectrum disorder. Such tests enable parents and physicians to determine whether the child's abnormality is caused by a genetic defect. If so, the condition can be addressed in a number of ways including watching for health conditions associated with the abnormality, providing eligibility for services such as speech or physical therapy and to evaluate the risk to future pregnancies. Under conditional approval, CombiMatrix will be able to market the test in New York while the test is under Clinical Laboratory Reference System review. Upon completion of the review, either the test will receive full marketing approval or additional information will be required in order to achieve final approval.

CombiMatrix Corporation Amends Certificate of Incorporation

CombiMatrix Corporation at its annual meeting of stockholders held on June 17, 2014, has approved an amendment to the company's Certificate of Incorporation to increase the maximum number of shares of the company's common stock authorized for issuance from 25,000,000 to 35,000,000 shares.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBMX:US $2.22 USD -0.05

CBMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBMX.
View Industry Companies
 

Industry Analysis

CBMX

Industry Average

Valuation CBMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMBIMATRIX CORP, please visit www.combimatrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.